옵션 체인은 다양한 행사가격과 만기일에 대한 Hut 8의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Hut 8에 대한 시장 심리를 평가합니다..

Hut 8 (NASDAQ:HUT) 주식, 옵션 체인

Hut 8

Hut 8 Mining

Hut 8 Corp is an energy infrastructure operator and Bitcoin miner with self-mining, hosting, managed services, and traditional data center operations across North America. The company has four reportable business segments: Power, Digital Infrastructure, Compute, and Other. It derives maximum revenue from the Compute segment which consists of Bitcoin Mining, GPU-as-a-Service, and Data Center Cloud operations. Its geographical segments include the United States and Canada, of which it generates the majority of revenue from the United States.

News

Movers

$BTC

CLSK

MARA

RIOT

헛 8(NASDAQ:HUT)의 주식이 다른 가상화폐 관련 주식들과 함께 화요일 상승했다.

화요일 헛 8 주식이 12% 이상 급등 마감: 무슨 일이?

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

MSTR

비트코인(CRYPTO: BTC) 채굴 회사인 마라 홀딩스(NASDAQ:MARA)는 15,574 BTC를 15억 3천만 달러에 인수했다고 발표했다. 이는 11월과 12월에 발행된 제로쿠폰 전환사채를 통해 조달한 19억 2천5백만 달러로 자금을 마련한 것이다.

채굴업체 마라 홀딩스, MSTR 플레이북 수용하며 15억 3천만 달러 상당 비트코인 인수

Tech

암호화폐 연계 회사 헛 8(NASDAQ:HUT), 마라 홀딩스(NASDAQ:MARA), 라이엇 플랫폼스(NASDAQ:RIOT)의 주가가 월요일(2일) 급락했다. 최근 비트코인(CRYPTO:BTC/USD) 가격이 10만 달러에 근접 상승한 이후 조정을 겪었기 때문이다.

헛 8, 마라 홀딩스 등 암호화폐 관련 주식이 월요일에 급락한 이유는?

Hut 8 Corp

HUTCHISON TLCM UNSP/ADR by Hutchison Telecommunications Hong Kong Holdings Ltd.

Hutchison Telecommunications Hong Kong Holdings Ltd

HUTN Inc

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China) Ltd

HUTCHMED CHINA LTD by Hutchison China Ltd.

HUTCHISON PORT HLDGS TR by Hutchison Port Holdings Trust

Hutchison Port Holdings Trust

HUTCHISON PORT H UNSP/ADR by Hutchison Port Holdings Trust

HUTCHISON TELECM HK HLDGS by Hutchison Telecommunications Hong Kong Holdings Ltd.

HUTECH21 CO LTD NEW by Hutech21 Co., Ltd.

Hutech21 Co Ltd

Barclays analyst Betty Jiang maintains Exxon Mobil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) with a Overweight and lowers the price target from $137 to $135.

Price Target

Analyst Ratings

Barclays Maintains Overweight on Exxon Mobil, Lowers Price Target to $135

General

SCWO

374Water Announces Successful Treatment And Destruction Of LNAPL-Based PFAS From Impacted Groundwater Samples From US Navy

Barclays analyst Betty Jiang maintains Expand Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXE#NASDAQ">EXE</a>) with a Equal-Weight and lowers the price target from $117 to $115.

Barclays Maintains Equal-Weight on Expand Energy, Lowers Price Target to $115

High Wire Networks Partners With SentinelOne To Provide Managed Detection And Response And Managed Security Services Provider Solutions

Valens Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLN#NYSE">VLN</a>) today announced that it hosted successful interoperability testing with seven other vendors of MIPI A-PHY silicon: Analogix, ESWIN Technology, Motorcomm, OmniVision Technologies, Silergy, SimChip, and Velink. The testing is a key step towards broad adoption of A-PHY in China, where there is already a particularly robust ecosystem of companies developing&nbsp;products around this technology, and signals significant momentum of this technology for the global automotive industry.
MIPI A-PHY is the first standard in the automotive industry for in-vehicle asymmetric high-speed connectivity. Valens is a leader in MIPI A-PHY, offering the first chipsets on the market to comply with the standard and the first to <a href="https://www.valens.com/newsroom/valens-semiconductor-announces-three-automotive-design-wins-from-leading-european-oems-for-its-va7000-mipi-a-phy-chipsets/">achieve design wins</a> with OEMs.
Achieving interoperability is a pivotal milestone in the establishment of an industry standard, backed by a strong ecosystem. This type of standard would increase supply chain security and decrease dependency on vendor pricing. As part of the weeks-long interoperability testing, which took place across multiple events, Valens established A-PHY links with all vendors, indicating strong product maturity for A-PHY silicon.

Global

Valens Semiconductor Announces That It Hosted Interoperability Testing With Seven Other Vendors Of MIPI A-PHY Silicon; Testing Is A Key Step Towards Broad Adoption Of A-PHY In China

Barclays analyst Betty Jiang maintains EOG Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EOG#NYSE">EOG</a>) with a Equal-Weight and lowers the price target from $146 to $144.

Barclays Maintains Equal-Weight on EOG Resources, Lowers Price Target to $144

ALVO

Alvotech And Dr. Reddy's Announce FDA Acceptance Of Biologic License Application For AVT03

ACOG

Alpha Cognition Announces The Official Commercial Launch Of ZUNVEYL, A New Treatment For Mild To Moderate Alzheimer's Disease

JFBR

Jeffs' Brands Closes Acquisition Of Pure NJ Logistics

BlackSky Spectra&#xAE; tasking and analytics platform architecture optimized to deliver industry-leading secure, AI-derived real-time intelligence in minutes
BlackSky Technology Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKSY#NYSE">BKSY</a>) recently completed a critical design review (CDR) with a major international defense customer successfully confirming that the company's next-generation architecture, powered by its Gen-3 constellation, will deliver industry-leading secure, AI-derived real-time intelligence within minutes.

BlackSky Technology Inc. Class A Common Stock

BKSY

BlackSky Recently Completed A Critical Design Review With A Major International Defense Customer Successfully Confirming That The Co's Next-Generation Architecture, Powered By Its Gen-3 Constellation

Barclays analyst Betty Jiang maintains Diamondback Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>) with a Overweight and lowers the price target from $210 to $200.

FANG

Barclays Maintains Overweight on Diamondback Energy, Lowers Price Target to $200

Contracts

INSE

Inspired Entertainment Extends Contract With Buzz Bingo

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4384149-1&amp;h=862988185&amp;u=https%3A%2F%2Fwww.lightpath.com%2F&amp;a=LightPath+Technologies%2C+Inc.">LightPath Technologies, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPTH#NASDAQ">LPTH</a>) ("LightPath," the "Company," or "we"), a leading provider of next-generation optics and imaging systems for both defense and commercial applications, today announced its recently acquired subsidiary G5 Infrared ("G5"), a leading high-end infrared camera systems manufacturer, received an $4.8 million initial qualification order for infrared cameras with a new defense industry customer, for delivery in calendar year 2025.
LightPath's cooled infrared cameras are the system of choice for all-weather security and surveillance. With outstanding target detection and recognition capabilities, the camera combines high-end performance with reliability and ease of use.

LPTH

LightPath Technologies Announces Its Recently Acquired Subsidiary G5 Infrared, Received An $4.8M Initial Qualification Order For Infrared Cameras With A New Defense Industry Customer, For Delivery In Calendar Year 2025

WIIM

SRPT

Sarepta Therapeutics shares are trading lower after the company reported a patient death following treatment with Elevidys.

Biotech

CANF

Can-Fite BioPharma Received FDA Approval For Compassionate Use Treament Of U.S. Based Pancreatic Cancer Patient With Anti-Cancer Drug Namodenoson

Barclays analyst Betty Jiang maintains Coterra Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRA#NYSE">CTRA</a>) with a Overweight and raises the price target from $37 to $38.

CTRA

Barclays Maintains Overweight on Coterra Energy, Raises Price Target to $38

<a href="https://investorrelations.sarepta.com/static-files/0d505d91-6722-4528-aae0-1e99fcbc37e5" title="https://investorrelations.sarepta.com/static-files/0d505d91-6722-4528-aae0-1e99fcbc37e5">https://investorrelations.sarepta.com/static-files/0d505d91-6722-4528-aae0-1e99fcbc37e5</a>

Health Care

Sarepta Therapeutics Reports A Patient Death With Duchenne Muscular Dystrophy Following Treatment With Elevidys, Having Suffered Acute Liver Failure

Study confirms clinical utility of EsoGuard as a non-invasive triage tool to significantly increase positive yield of invasive upper endoscopy
NEW YORK, March 18, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4385588-1&amp;h=2938957453&amp;u=https%3A%2F%2Fwww.luciddx.com%2F&amp;a=Lucid+Diagnostics+Inc.">Lucid Diagnostics Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCD#NASDAQ">LUCD</a>)&nbsp;("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAVM#NASDAQ">PAVM</a>), today announced that its ENVET-BE clinical utility study has been accepted for publication in&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4385588-1&amp;h=4046851265&amp;u=https%3A%2F%2Fwww.gastroenterologyandhepatology.net%2F&amp;a=Gastroenterology+%26+Hepatology">Gastroenterology &amp; Hepatology</a>—the fifth peer-reviewed publication of clinical utility data for Lucid's <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4385588-1&amp;h=1689541140&amp;u=http%3A%2F%2Fwww.esoguard.com%2F&amp;a=EsoGuard%C2%AE+Esophageal+DNA+Test">EsoGuard&#xAE; Esophageal DNA Test</a>, and the second to present findings from a real-world screening population. The manuscript, entitled <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4385588-1&amp;h=4171221918&amp;u=https%3A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.1101%2F2024.07.26.24311013v1.full&amp;a=Enhancing+the+Diagnostic+Yield+of+EGD+for+Diagnosis+of+Barrett%27s+Esophagus+Through+Methylated+DNA+Biomarker+Triage">Enhancing the Diagnostic Yield of EGD for Diagnosis of Barrett's Esophagus Through Methylated DNA Biomarker Triage</a>,&nbsp;demonstrates that confirmatory upper endoscopy (EGD) performed in EsoGuard-positive patients had a substantially higher diagnostic yield for detecting esophageal precancer (Barrett's Esophagus or BE) than the expected yield of screening EGD alone in at-risk patients.

LUCD

PAVM

Lucid Diagnostics' ENVET-BE Clinical Utility Study Of EsoGuard Esophageal Precancer Testing Accepted For Peer-Reviewed Publication; Study Confirms Clinical Utility Of EsoGuard As A Non-Invasive Triage Tool To Significantly Increase Yield Of Invasive Upper Endoscopy

U.S. stock futures were lower this morning, with the Dow futures falling around 0.1% on Tuesday.
Shares of Hallador Energy Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HNRG#NASDAQ">HNRG</a>) fell sharply in today's pre-market trading following <a href="https://www.benzinga.com/quote/HNRG/earnings">a fourth-quarter sales miss.</a>
Hallador Energy reported quarterly earnings of 7 cents per share which beat the analyst consensus estimate of a loss of 13 cents per share. The company reported quarterly sales of $94.200 million which missed the analyst consensus estimate of $95.450 million.
Hallador Energy shares dipped 6.8% to $10.70 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Arlo Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARLO#NYSE">ARLO</a>) shares tumbled 9.3% to $10.01 in pre-market trading after gaining 4% on Monday.</li>
<li>Ivanhoe Electric Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IE#NYSE">IE</a>) declined 6.9% to $5.92 in pre-market trading.</li>
<li>Verastem, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) shares declined 6% to $6.80 in pre-market trading after gaining 4% on Monday.</li>
<li>Resolute Holdings Management, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RHLD#NASDAQ">RHLD</a>) fell 4.8% to $42.05 in pre-market trading.</li>
<li>Bausch Health Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHC#NYSE">BHC</a>) fell 4.1% to $6.75 in pre-market trading.</li>
<li>Kenon Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEN#NYSE">KEN</a>) fell 3.4% to $34.04 in pre-market trading after gaining 3% on Monday.</li>
<li>Akebia Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) fell 3.3% to $2.32 in pre-market trading.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) slipped 1.6% to $234.30 in pre-market trading. Tesla shares fell 4.8% on Monday after Mizuho cut its price target on the stock from $515 to $430.  </li>
</ul>
Now Read This:<a href="https://www.benzinga.com/markets/25/03/44355158/jim-cramer-says-this-tech-stock-is-a-meme-stock-recommends-buying-accenture"> </a>
<ul>
<li><a href="https://www.benzinga.com/markets/25/03/44355158/jim-cramer-says-this-tech-stock-is-a-meme-stock-recommends-buying-accenture">Jim Cramer Calls This Stock A &#8216;Meme Stock,&#8217; Recommends Buying Accenture</a></li>
</ul>

Pre-Market Outlook

Trading Ideas

AKBA

ARLO

HNRG

RHLD

TSLA

VSTM

Hallador Energy, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Barclays analyst Betty Jiang maintains APA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>) with a Equal-Weight and lowers the price target from $27 to $25.

Comments

Hut 8

Hut 8 (HUT) 옵션

Loading...

뉴스

파트너 / 기고자

벤징가 글로벌